• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Metabolic Endocrinology Type I Diabetes Product Image

Metabolic Endocrinology Type I Diabetes

  • ID: 599554
  • March 2008
  • 69 pages
  • Life Science Analytics

"Metabolic Endocrinology Type I Diabetes " contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each ’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Type I Diabetes Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects



--Top Companies in late stage Type I Diabetes Projects
--AutoImmune Inc
--AmCyte Inc.
--BTG plc
--Bayhill Therapeutics, Inc.
--DeveloGen AG
--Chong Kun Dang Pharmaceutical Corp.
--Pharm)
--Diamyd Medical AB
--Diabetology Ltd
--Generex Biotechnology Corporation
--Eli Lilly & Co
--GlaxoSmithKline plc
--Genzyme Corporation
--Living Cell Technologies Ltd
--Insmed Incorporated
--Novocell, Inc.
--MacroGenics Inc.
--Procter & Gamble Company
--Osiris Therapeutics Inc
--Tolerx, Inc.
--Protein Sciences Corporation

--Top Companies in early stage Type I Diabetes Projects
--Alba Therapeutics Corporation
--AdPharma, Inc.
--Eli Lilly & Co
--DiaKine Therapeutics, Inc.
--Geron Corporation
--FIT Biotech Oyj Plc.
--Living Cell Technologies Ltd
--Lipoxen
--MultiCell Technologies Inc
--MicroIslet, Inc.
--Oramed Pharmaceuticals Inc
--Novocell, Inc.
--ReNeuron Group plc
--Plantigen Inc.
--Sernova Corp
--erly Pheromone Sciences Corp)
--Schering-Plough Corp
--VGX Pharmaceuticals, Inc
--Target-In Ltd.

Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos